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Abstract
Background:  World Health Organization (WHO) targets for acute flaccid paralysis (AFP)
surveillance, including the notification of a minimum rate of AFP among children, are used to assess
the adequacy of AFP surveillance for the detection of poliovirus infection. Sensitive surveillance for
poliovirus infection in both developed and developing countries is essential to support global
disease eradication efforts. We applied recently developed methods for the quantitative evaluation
of disease surveillance systems to evaluate the sensitivity of AFP surveillance for poliovirus infection
in Australia.
Methods: A scenario tree model which accounted for administrative region, age, population
immunity, the likelihood of AFP, and the probability of notification and stool sampling was used to
assess the sensitivity of AFP surveillance for wild poliovirus infection among children aged less than
15 years in Australia. The analysis was based on historical surveillance data collected between 2000
and 2005. We used a surveillance time period of one month, and evaluated the ability of the
surveillance system to detect poliovirus infection at a prevalence of 1 case per 100 000 persons and
1 case per million persons.
Results: There was considerable variation in the sensitivity of AFP surveillance for poliovirus
infection among Australian States and Territories. The estimated median sensitivity of AFP
surveillance in Australia among children aged less than 15 years was 8.2% per month at a prevalence
of 1 case per 100,000 population, and 0.9% per month at a prevalence of 1 case per million
population. The probability that Australia is free from poliovirus infection given negative
surveillance findings following 5 years of continuous surveillance was 96.9% at a prevalence of 1
case per 100,000 persons and 56.5% at a prevalence of 1 case per million persons.
Conclusion: Given the ongoing risk of poliovirus importation prior to global eradication, long
term surveillance is required to provide a high degree of confidence in freedom from poliovirus
infection in Australia, particularly if a low prevalence of infection is assumed. Adherence to the
WHO surveillance targets would considerably improve the sensitivity of surveillance for poliovirus
infection in Australia.
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Background
The Global Polio Eradication Initiative commenced in
1988 following the adoption of a resolution to eradicate
poliomyelitis (polio) at the World Health Assembly [1].
The worldwide polio eradication campaign has been suc-
cessful in achieving a 99% reduction in the global inci-
dence of polio since 1988 [2]. The number of countries
that have not yet interrupted indigenous transmission of
wild poliovirus was reduced to 4 in 2006 [3], although the
final stages of eradication are proving challenging [4].
Since 2003, at least 22 countries that were previously
polio-free have reported re-infection [5]. Three large out-
breaks following importation into the previously polio-
free countries of Yemen, Indonesia and Somalia were
largely responsible for the increase in reported cases of
polio during 2005, and this was the first year in which
more cases were reported from re-infected countries than
from endemic countries [6]. These outbreaks emphasise
the importance of effective vaccination, disease surveil-
lance and response systems to polio eradication efforts,
irrespective of the local disease incidence [7].
Poliovirus is an enterovirus which has no extrahuman res-
ervoir [8]. In developing countries, polio primarily affects
infants and children less than 5 years of age. Infection is
spread most commonly by the faecal-oral route, particu-
larly in the presence of poor hygiene and sanitation. Oral-
oral respiratory transmission is thought to be more com-
mon in industrialised countries [9].
In most people poliovirus infection is subclinical. A small
proportion of cases experience viral replication in the cen-
tral nervous system which may lead to permanent neuro-
nal destruction and paralysis [9]. As a result, poliovirus
infection is most commonly recognised by the onset of
acute flaccid paralysis (AFP). Acute flaccid paralysis is esti-
mated to occur in between 0.1% and 2% of poliovirus
infections, with residual paralysis occurring in between
0.1% and 1% of infections [9]. The high proportion of
subclinical cases contributes to difficulties in disease erad-
ication [10]. Laboratory-based surveillance for poliovirus
infection among reported cases of AFP is used to monitor
and control poliovirus infection, as there are no criteria
that permit the identification of polio by clinical signs and
symptoms alone.
In October 2000, the World Health Organisation (WHO)
certified the Western Pacific Region, which includes Aus-
tralia, as polio-free [11]. To be certified as polio-free,
countries must have an absence of wild poliovirus for 3
years in the presence of adequate AFP surveillance in chil-
dren under the age of 15 years, have a national committee
to validate and submit the surveillance documentation,
and have mechanisms to detect and respond to the intro-
duction of wild poliovirus [12]. Prior to the 2007 impor-
tation of wild poliovirus into Australia via a traveller
returning from Pakistan [13], the last recorded importa-
tion of wild poliovirus in Australia occurred in 1977 [14].
The Australian Paediatric Surveillance Unit commenced
AFP surveillance in children aged less than 15 years in
1995 [15]. In order to maximise the ability of surveilance
to rapidly detect imported cases, World Health Organiza-
tion guidelines require all cases of AFP in children aged
less than 15 years be notified and investigated as prospec-
tive polio cases, including the collection of 2 stool sam-
ples 24 hours apart and within 14 days of the onset of
paralysis [15]. The requirement to investigate all cases of
AFP is considered critical to support the sensitivity of
polio surveillance. Notification of AFP and stool investi-
gation allow the detection of poliovirus transmission
through the identification of both classical and atypical
cases, as well as providing a basis for assessment of the
quality of surveillance [12].
The established performance indicators for AFP surveil-
lance require that reporting should be complete, timely,
and represent the geography and demography of the
country; that at least one case of non-polio AFP should be
detected annually per 100,000 population aged less than
15 years; that full clinical and virological investigations
should be completed for all AFP cases, with at least 80%
having adequate faecal samples collected for analysis at an
accredited laboratory; and that follow-up examination for
residual paralysis should occur in at least 80% of cases
[12].
Effective AFP surveillance in countries which have been
declared polio-free is essential to support polio eradica-
tion through the detection of imported and vaccine-asso-
ciated polio cases, and AFP surveillance is required for
countries to retain their polio-free status [16]. Histori-
cally, Australia has been unable to maintain sufficiently
sensitive AFP surveillance [17,18] as the reported inci-
dence of AFP in Australia has often been below the
expected rate. Formal quantitative evaluation of AFP sur-
veillance is required to ensure that surveillance is ade-
quate to detect poliovirus infection at an appropriate
prevalence.
This analysis aimed to use existing data and scenario tree
modelling to provide an improved understanding of the
sensitivity of AFP surveillance among children aged less
than 15 years in Australia. Scenario tree modelling allows
explicit quantification of the sensitivity of AFP surveil-
lance, and examines the impact of multiple factors on sur-
veillance performance. Comprehensive assessment ofBMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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surveillance system performance can facilitate the efficient
allocation of resources for disease surveillance and con-
trol.
Methods
We used a stochastic scenario tree model [19] to evaluate
the sensitivity of AFP surveillance for wild poliovirus
infection among children aged less than 15 years in Aus-
tralia, and estimate the probability of Australia of being
free from wild poliovirus infection on the basis of this sur-
veillance. The model has two main assumptions: that all
surveillance results in the period under analysis are nega-
tive, and that the surveillance system does not produce
false positive results [19]. The second assumption of per-
fect specificity implies that adequate information is avail-
able for each eligible case of AFP identified to resolve
potential false positive results and allow a definitive diag-
nosis to be made.
The assumption of perfect specificity is supported by
WHO surveillance standards [12] which require a mini-
mum rate of AFP case notification and stool sampling, the
timely and complete collection of clinical information,
follow-up assessment for a minimum of 80% of cases, and
the use of accredited laboratories and an expert review
committee. Stool testing is considered the gold standard
for the exclusion of polio in the presence of AFP [15].
Scenario tree modelling requires the surveillance outcome
to be dichotomous. Within the existing AFP surveillance
system three outcomes are possible for notified AFP cases:
confirmed poliomyelitis due to poliovirus, non-poliomy-
elitis AFP, and poliomyelitis compatible. The latter classi-
fication is used in cases where the surveillance system
failed to collect adequate specimens within the recom-
mended time to allow definitive case classification.
Although potentially poliomyelitis compatible cases were
reported during the study period (2000-2005), no cases
were classified as poliomyelitis compatible during the
study period, providing data that are consistent with a
dichotomous outcome model.
A scenario tree model was constructed to describe the clin-
ical diagnostic system used for AFP surveillance among
children aged less than 15 years in Australia, with the sur-
veillance unit being individuals. Variables that describe
the structure of the population and influence the proba-
bility of disease or the probability of detecting disease,
including factors which may bias sampling, were incorpo-
rated in the scenario tree as nodes. The scenario tree struc-
ture is summarised in Figure 1. The clinical decision-
making process and the Australian Polio Expert Commit-
tee surveillance data review process are not represented in
the scenario tree as they are not assumed to be associated
with any decrease in the sensitivity of the surveillance sys-
tem. Justification for node selection and the source of
parameter estimates is detailed in the following section,
and the parameters used are summarised in Table 1. This
research was approved by the Human Research Ethics
Committee of Curtin University of Technology.
Nodes and node probabilities
Jurisdiction
State and Territory governments are principally responsi-
ble for providing clinical health services to the resident
population within each of these administrative subdivi-
sions. A category node was incorporated into the model to
reflect the underlying structure of health service delivery
and reporting, and allow an assessment of surveillance
sensitivity by jurisdiction. Branch proportions describe
the proportion of the Australian population residing in
each State or Territory based on data from the 2006 Cen-
sus [20].
Age
Age was incorporated into the model to reflect the age-
specific targeting of AFP surveillance. Age is also a risk fac-
tor for infection [9], with the incidence of poliovirus
infection decreasing with age in the absence of immunisa-
tion. Infection later in life is also associated with increased
disease severity [21]. Three age categories were incorpo-
rated in the scenario tree model. Branch proportions
describe the proportion of the population aged less than
5 years, 5 to less than 15 years, and 15 years or more,
based on data from the 2006 Census [20].
Proportion immune
A risk category node was incorporated in the model to rep-
resent the population prevalence of immunity to poliovi-
rus infection. Live attenuated (oral) polio vaccine was the
predominant vaccine used during the study period; it was
removed from the Australian immunisation schedule in
November 2005 [22]. Two indicators of the population
prevalence of immunity were available: estimates from a
national serosurvey based on sera collected between 1996
and 1999 [23], and data from the Australian Childhood
Immunisation Register (ACIR) [24] which are considered
to give a minimum estimate of vaccination coverage due
to delayed notification and vaccination [25,26]. Serosur-
vey data are considered to provide a better indicator of the
proportion of the population who are susceptible to
poliovirus infection, as immune status is also influenced
by naturally acquired immunity and waning immunity
[27]. Serosurvey estimates also eliminate potential biases
associated with jurisdiction-specific differences in immu-
nisation notifications [28].
National serosurvey point estimates and 95% confidence
intervals for immunity to wild type 1 poliovirus infection
[23] were used to parameterise Beta-PERT distributions
(Table 1) as wild type 1 poliovirus is the virus most com-
monly associated with importations and outbreaks [29].BMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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Table 1: Parameter estimates used in the scenario tree analysis of acute flaccid paralysis surveillance in Australia
Node Category Probability or proportion
Jurisdiction ACT 0.016
NSW 0.330
NT 0.010
QLD 0.197
SA 0.076
TAS 0.024
VIC 0.248
WA 0.099
Age <5 years
ACT 0.062
NSW 0.064
NT 0.082
QLD 0.066
SA 0.058
TAS 0.060
VIC 0.062
WA 0.064
5 to <15 years
ACT 0.129
NSW 0.134
NT 0.165
QLD 0.141
SA 0.128
TAS 0.137
VIC 0.131
WA 0.139
Proportion immune Immune
<5 years (0.85,0.91,0.95)†
5 to <15 years (0.81,0.87,0.91)†
15+ years (0.75,0.80,0.85)†
Infection status Infected 0.00001
Acute Flaccid Paralysis Yes
<5 years (0.001,0.005,0.01)†
5 to <15 years (0.005,0.01,0.02)†
15+ years (0.005,0.01,0.02)†
Notified Yes
ACT Beta(1.3,61931.7)‡
NSW Beta(18.5,1298900.5)
NT Beta(2.2,47604.8)‡
QLD Beta(11.3,806522.7)‡
SA Beta(2.7,280823.3)‡
TAS Beta(1.7,94022.3)‡
VIC Beta(6.2,950388.8)‡
WA Beta(2.7,396433.3)‡
Stool sample Yes
ACT Beta(2,2)
NSW Beta(23,84)
NT Beta(1,8)
QLD Beta(29,35)
SA Beta(3,9)
TAS Beta(2,4)
VIC Beta(10,23)
WA Beta(4,8)
Test Positive (0.95,0.97,0.99)†
†Beta-PERT (Program Evaluation and Review Technique) distribution (lower, most likely, upper)
‡Calculated as the ratio of this beta distribution divided by 10-5, with the result constrained to have an upper limit of 1.BMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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Scenario tree structure for acute flaccid paralysis surveillance in Australia Figure 1
Scenario tree structure for acute flaccid paralysis surveillance in Australia.
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Age-specific serosurvey estimates were weighted by popu-
lation proportions [20] to provide estimates for the age
categories used in this analysis. Due to a lack of evidence
on the strength of the protective effect associated with
being sero-positive [23], we estimated that the risk of
infection among sero-positive individuals compared with
sero-negative individuals as varying between 1/500 and 1/
1500 with a mean of 1/1000.
Although the prevalence of immunity to poliovirus infec-
tion is an important factor influencing the likelihood of
infection, this variable does not affect the estimated sensi-
tivity of surveillance in the current scenario tree model, as
there is no differential surveillance of cases according to
sero-status. That is, in this model the detection node
parameters are identical for both the sero-positive and
sero-negative individuals, and as such, parameter esti-
mates based on serosurvey data and ACIR data produce
equivalent results. However, the prevalence of immunity
is included in this analysis for completeness, and will be
an essential component of models that incorporate tar-
geted surveillance strategies based on susceptibility to
infection.
Infection status
As the sensitivity of a surveillance system depends on the
prevalence of infection in the population, evaluation
needs to be performed with reference to a selected popu-
lation prevalence of infection, or 'design prevalence' [30],
which is specified at the infection status node of the sce-
nario tree. The sensitivity of AFP surveillance was evalu-
ated based on infection being present at or above design
prevalences of 10-5  (approximately 199 infections
expected nationally) and 10-6 (approximately 20 infec-
tions expected nationally). A population prevalence of
infection of 10-6 may approach a level where the odds of
the virus persisting in the population are low [31].
The infection status node also incorporates the effect of
age on the risk of infection. Developing countries with
endemic poliovirus transmission typically observe most
paralytic poliomyelitis cases in children below 5 years of
age [9,32]. Children are thought to play a dominant role
in the transmission of polioviruses within populations
[27], although the effect of age alone on the prevalence
and severity of poliomyelitis is difficult to specify with
confidence [33]. Poor sanitation and hygiene is thought
to contribute to the age profile of cases in developing
countries [34]. In developed countries, population immu-
nity, including historical deficiencies in vaccination cover-
age, is likely to be the most important determinant of the
age distribution of poliomyelitis cases [35,36].
Two different estimates were used to describe the age-
related risk of poliovirus infection due to uncertainty
associated with the effect of age. For the first, no difference
in the risk of infection by age was specified. For the sec-
ond, parameters were based on published estimates of the
age distribution of poliomyelitis cases in developed coun-
tries in the absence of immunisation [9]. The risk of infec-
tion for persons aged less than 5 years was 3 times greater
than for persons aged 15 years or more, and the risk of
infection for persons aged 5 to less than 15 years was 2
times greater than for persons aged 15 years or more.
Acute Flaccid Paralysis
The probability of individuals with poliovirus infection
having AFP is an important determinant of case detection
rates, and is commonly estimated to vary between 0.001
and 0.01 or 0.02 [21,37,38], with a mean around 0.005
[38,39]. Difficulties in detecting and defining non-para-
lytic poliovirus infections, and accounting for the effects
of prior immunity add to the uncertainty in age-specific
rates of AFP [33].
Data from epidemics among largely naive populations
suggest that young children are likely to have mild infec-
tions, and that adults are more likely to have severe para-
lytic infections [33]. Another review [21] also suggests
that there is an increase in the ratio of paralytic cases to
infections with increasing age, with an approximate two-
fold increase in risk of paralytic rates among older chil-
dren or young adults compared with younger children.
Based on these data [21], we specified the rate of AFP
among persons aged 5 years or more to be twice the rate
among individuals aged less than 5 years.
Notified
Paediatric cases of AFP are considered to come to the
attention of the health care system in developed countries
due to the severity of the condition [40]. For each Austral-
ian jurisdiction, the probability of notification of a case of
AFP was based on a comparison of the average probability
of notification of AFP cases between 2000 and 2005 per
100,000 to the recommended AFP case notification rate of
1 per 100,000 children aged less than 15 years [12], using
data provided by the Australian National Poliovirus Refer-
ence Laboratory. A beta distribution was used to model
the overall probability of notification between 2000 and
2005 for each jurisdiction, and the ratio of this probability
per 100,000 population to the expected notification rate
(constrained to have an upper limit of 1.0) was used in the
scenario tree. There is little evidence to suggest that the
true AFP notification rate in Australia is lower than that
designated by the WHO [41,42].
Stool sample
The probability of adequate clinical samples being
obtained for notified cases was modelled using a beta dis-
tribution based on the proportion of notified cases forBMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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each jurisdiction between 2000 and 2005 that had two
stool samples submitted for analysis within the recom-
mended time frame, and the number of AFP cases notified
by each jurisdiction over the same period.
Test
The final detection node represents the diagnostic sensi-
tivity of stool testing for the presence of poliovirus. A pub-
lished estimate of the sensitivity of laboratory testing for
poliovirus based on nine years of AFP surveillance data of
97% [43] was used as the basis for the sensitivity estimate
used in the model, allowing for uncertainty. Comprehen-
sive follow-up testing of positive test results ensures per-
fect specificity.
Calculation of sensitivity
The sensitivity of the surveillance system was evaluated
per month due to the reasonably short incubation period
of polio, with cases generally occurring 1-3 weeks follow-
ing exposure [9]. The unit sensitivity of AFP surveillance
(the probability that an individual will yield a positive
surveillance finding, given that the population is infected
at the design prevalence) is calculated by summing the
probabilities for all positive outcomes of the scenario tree
[19]. The probability of each positive outcome of the sce-
nario tree is calculated by multiplying all node probabili-
ties, proportions and risks associated with that outcome.
To calculate the system sensitivity of the surveillance sys-
tem (SSe) the unit sensitivity is raised to the power of the
number of units processed in the surveillance system (the
Australian population), using Equation 1. The system sen-
sitivity for each jurisdiction was computed similarly,
based on the population proportion in each jurisdiction.
To estimate the probability of freedom from poliovirus
infection, a prior estimate of the level of certainty of Aus-
tralia being free from wild poliovirus infection is required
for the initial surveillance month. Although historical sur-
veillance data suggest that the probability of Australia
being free from poliovirus infection is high, an imported
case was detected in 2007 [13]. The failure of poliovirus to
establish in Australia given importation can be attributed
to high levels of population immunity; however, immu-
nity is not uniformly distributed and outbreaks could still
occur. A neutral prior probability of 0.5 was used to pro-
vide a conservative estimate of the prior certainty of free-
dom from poliovirus infection following a known
importation.
To estimate the probability of freedom from poliovirus
infection for subsequent months of surveillance, the value
of surveillance data must be discounted, as infection may
be imported, or may have been present in the population
during the previous surveillance period but remained
undetected. In the 30-year period between 1978 and
2007, only 1 imported case of wild poliovirus infection
was detected. Based on historical data, the probability of
poliovirus introduction into Australia is therefore 1/360
per month (assuming that all imported cases are
detected), and the probability of establishment of wild
poliovirus infection in Australia at the minimum design
prevalence of 10-6 is 0/360 (assuming all outbreaks have
been detected). This estimate can be modelled as a
Beta(1,361) distribution based on the Bayesian estimate
of a population proportion derived from the observation
of s successes out of n samples being Beta(s+1, n-s+1)
[44].
A more conservative estimate of the rate of importation of
wild poliovirus infection into Australia would account for
the likelihood of asymptomatic infection and disease
establishment. Given the likelihood of asymptomatic
infection decreases with age, the probability of wild polio-
virus introduction in travellers is likely to be approxi-
mately 100 times the detected importation rate, or 1/3.6
per month. Based on recent work indicating a very low
risk of wild poliovirus outbreaks in high income countries
[39], we conservatively estimated the risk of establish-
ment of poliovirus infection in Australia given introduc-
tion to be 0.001. A review of wild poliovirus importation
into 21 previously polio-free countries [29] also suggests
that uniformly high vaccination coverage levels in Aus-
tralia are strongly protective against the establishment of
introduced wild poliovirus infection. The probability of
introduction and establishment, accounting for the likely
proportion of asymptomatic infection, was estimated to
be 1/3600 (1/3.6*1/1000), and was modelled as a
Beta(2,3600) distribution.
Simulation parameters
The model was implemented using Microsoft Excel 2003.
The @RISK add-in for Excel version 4.5.2 (Palisade Cor-
poration) was used to estimate the sensitivity of the sur-
veillance system and perform stochastic simulations by
sampling from the specified distributions in the model.
The simulation used a fixed random number seed of 1,
and 10,000 iterations were performed using latin hyper-
cube sampling. Results are summarised using the median
and range (5th-95th percentiles) of the outcome variable
distributions.
Comparison with WHO criteria
The sensitivity of AFP surveillance based on historical data
was compared with the sensitivity of surveillance implied
by the WHO guidelines (assuming all States and Territo-
ries notify cases of AFP at a rate of 1 per 100,000 or higher
and have an 80% probability of submitting two stool
SSe unit sensitivity
units processed =− − 11 ()  
  (1)BMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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samples) as a sensitivity ratio [19]. All other node proba-
bilities and relative risks remained consistent between the
two sensitivity estimates.
Results
Surveillance system sensitivity
The estimated median monthly sensitivity of AFP surveil-
lance for poliovirus infection in Australia among children
aged less than 15 years, assuming no difference in the risk
of infection with age, was 8.2% (5th-95th percentiles 5.3-
12.1%, mean 8.4%) for a design prevalence of 10-5, and
0.9% (5th-95th percentiles 0.5-1.3%, mean 0.9%) for a
design prevalence of 10-6 respectively. These results repre-
sent the probability of observing one or more positive test
results for poliovirus in a child with AFP if the population
is infected at the design prevalence.
If the risk of infection was greater among younger chil-
dren, the estimated median monthly sensitivity of AFP
surveillance almost doubled to 13.8% (5th-95th percen-
tiles 9.1-19.7%, mean 14.0%) for a design prevalence of
10-5, and 1.5% (5th-95th  percentiles 1.0-2.2%, mean
1.5%) for a design prevalence of 10-6 respectively.
The probability of freedom from poliovirus infection in
Australia given consistent negative surveillance findings is
summarised in Table 2. Results assume a conservative ini-
tial prior probability of infection (0.5), use the highest
estimate of the probability of disease introduction
(Beta(1,361)), and allow for different assumptions about
the desired design prevalence for surveillance and the dis-
tribution of infection with age.
The probability of Australia being free from poliovirus
infection after 5 years of continuous negative surveillance
results, assuming no difference in the risk of infection
with age, was 96.9% for a design prevalence of 10-5, and
56.5% for a design prevalence of 10-6. If the risk of infec-
tion was greater among younger children, the probability
of Australia being free from poliovirus infection after 5
years was 98.7% for a design prevalence of 10-5, and
64.3% for a design prevalence of 10-6 (Table 2). Surveil-
lance for poliovirus infection at a design prevalence of 10-
6 is only able to support a high probability of freedom
from infection over long periods of surveillance, and the
5th and 95th percentile estimates indicate a high degree of
variability in the probability of freedom over long surveil-
lance periods.
Given a lower probability of disease introduction
(Beta(2,3600)), the probability of Australia being free
from poliovirus infection after 5 years, assuming no dif-
ference in the risk of infection with age, was 98.8% (5th-
95th percentiles 95.3-99.7%) for a design prevalence of 10-
5, and 60.9% (5th-95th  percentiles 56.0-66.9%) for a
design prevalence of 10-6. If the risk of infection was
greater among younger children, the probability of Aus-
tralia being free from poliovirus infection after 5 years was
99.7% (5th-95th percentiles 98.9-99.9%) for a design prev-
alence of 10-5, and 69.2% (5th-95th  percentiles 62.0-
77.5%) for a design prevalence of 10-6.
Comparison with WHO recommended surveillance
Historical data describing the rate of notification and
stool sampling among AFP cases in each jurisdiction
between 2000 and 2005 are presented in Table 3. All 95%
confidence intervals for AFP notification rates include 1
case per 100,000 children aged less than 15 years apart
from estimates for Victoria and Western Australia. The
exact binomial confidence interval is known to be con-
servative for rare events [45]; however, findings were not
appreciably different when the score method was used
(data not shown). Similarly, 95% confidence intervals for
the probability of stool sampling given notification do
not include the WHO target rate for all jurisdictions apart
from the Australian Capital Territory and Tasmania,
Table 2: Probability of freedom from poliovirus infection in Australia given continuous negative surveillance findings
Probability of freedom (%)‡
Design prevalence 10-5 10-6
Time period No age effect Age effect No age effect Age effect
6 months 61.9 (57.3-68.7) 70.2 (63.2-78.3) 50.1 (49.2-51.6) 51.6 (50.0-52.9)
1 year 72.2 (63.8-81.2) 84.2 (74.1-92.4) 51.4 (48.0-53.2) 53.2 (49.7-55.7)
2 years 86.2 (74.6-94.3) 95.6 (87.5-98.9) 52.8 (45.9-56.3) 56.2 (49.0-61.2)
3 years 92.8 (81.8-98.1) 98.0 (92.5-99.7) 54.0 (43.9-59.3) 59.0 (48.4-66.3)
4 years 95.6 (85.9-99.1) 98.6 (93.9-99.8) 55.3 (42.1-62.2) 61.8 (47.8-71.0)
5 years 96.9 (88.0-99.5) 98.7 (94.2-99.9) 56.5 (40.4-65.0) 64.3 (47.3-75.1)
10 years 97.8 (89.9-99.8) 98.8 (94.4-99.9) 61.9 (33.6-76.9) 74.5 (45.3-89.0)
20 years 97.8 (90.0-99.9) 98.8 (94.4-99.9) 69.3 (25.1-90.0) 83.8 (43.1-97.0)
‡Median (5th-95th percentile), probability of introduction Beta(1,361)BMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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which both have wide confidence intervals due to the
small number of cases observed.
The probability of freedom from poliovirus infection in
Australia, assuming surveillance practices meet the WHO
target AFP case notification and stool sampling rates for
each jurisdiction, is summarised in Table 4. As for Table 2,
results were generated assuming a conservative initial
prior probability of infection (0.5), and using the highest
estimate of the probability of disease introduction
(Beta(1,361)).
If WHO targets were met for case notification and stool
sampling rates, the median probability of Australia being
free from poliovirus infection after 5 years of continuous
negative surveillance results, assuming no difference in
the risk of poliovirus infection with age, was 99.4% for a
design prevalence of 10-5, and 77.3% for a design preva-
lence of 10-6. If the risk of infection was greater among
younger children, the median probability of Australia
being free from poliovirus infection after 5 years was
99.7% for a design prevalence of 10-5, and 89.7% for a
design prevalence of 10-6 (Table 4).
The estimated median sensitivity of AFP surveillance in
Australia based on historical case notification and stool
sampling rates, assuming no difference in the risk of infec-
tion with age and a design prevalence of 10-5 (8.2%) was
considerably lower than if WHO criteria were met for case
notification and stool sampling rates (23.8%; sensitivity
ratio 0.35). Assuming an increased risk of infection in
younger children, the sensitivity of surveillance based on
historical case notification and stool sampling rates
(13.8%) was also considerably lower than if WHO criteria
were met for case notification and stool sampling rates
(37.6%; sensitivity ratio 0.37). Findings were similar
when surveillance sensitivity was estimated using a design
prevalence of 10-6, where sensitivity ratios assuming no
Table 3: State and territory surveillance system sensitivity (2000-2005) at a design prevalence of 10-5
Jurisdiction Notification rate per 100,000/
year*
Probability of stool 
sampling**
Median sensitivity (%)† (5th-95th 
percentiles)
Sensitivity Ratio‡
ACT 0.54 (0.07-2.78) 0.50 (0.01-0.99) 0.21 (0.03-0.49) 0.50
NSW 1.35 (1.10-1.63) 0.21 (0.01-0.30) 2.31 (1.39-3.61) 0.27
NT 2.45 (0.99-5.05) 0.00 (0.00-0.41) 0.03 (0.002-0.13) 0.09
QLD 1.28 (0.98-1.64) 0.45 (0.32-0.58) 2.99 (1.87-4.54) 0.55
SA 0.59 (0.28-1.09) 0.20 (0.03-0.56) 0.40 (0.08-1.05) 0.21
TAS 0.71 (0.19-1.82) 0.25 (0.01-0.81) 0.20 (0.03-0.54) 0.31
VIC 0.54 (0.37-0.77) 0.29 (0.14-0.48) 1.44 (0.55-3.09) 0.23
WA 0.42 (0.20-0.77) 0.30 (0.07-0.65) 0.60 (0.13-1.62) 0.22
Australia 0.98 (0.86-1.11) 0.29 (0.23-0.35) 8.22 (5.32-12.06) 0.35
*Rate per 100,000 persons aged < 15 years per year, (lower 95% binomial exact CI: upper 95% binomial exact CI).
**Probability (lower 95% binomial exact CI: upper 95% binomial exact CI).
†Model assumes no influence of age on the likelihood of infection.
‡Ratio of the jurisdiction sensitivity and the WHO recommended jurisdiction sensitivity.
Table 4: Probability of freedom from poliovirus infection in Australia given continuous negative surveillance findings based on WHO-
recommended notification and stool sampling practices
Probability of freedom (%)‡
Design prevalence 10-5 10-6
Time period No age effect Age effect No age effect Age effect
6 months 83.0 (74.3-90.2) 94.0 (86.7-97.7) 53.4 (51.6-55.2) 56.3 (53.8-59.1)
1 year 95.4 (88.7-98.5) 99.2 (96.9-99.8) 56.7 (52.7-60.2) 62.3 (57.2-67.4)
2 years 99.1 (96.5-99.9) 99.7 (98.5-100.0) 62.8 (55.0-69.4) 72.6 (63.1-80.7)
3 years 99.4 (97.2-99.9) 99.7 (98.6-100.0) 68.4 (56.9-77.1) 80.5 (68.2-89.0)
4 years 99.4 (97.2-100.0) 99.7 (98.6-100.0) 73.2 (58.7-83.1) 86.0 (72.0-93.8)
5 years 99.4 (97.2-100.0) 99.7 (98.6-100.0) 77.3 (60.2-87.6) 89.7 (75.0-96.3)
10 years 99.4 (97.2-100.0) 99.7 (98.6-100.0) 88.7 (65.3-96.9) 95.4 (81.1-99.4)
20 years 99.4 (97.2-100.0) 99.7 (98.6-100.0) 92.7 (68.2-99.3) 96.0 (82.1-99.7)
‡Median (5th-95th percentile), probability of introduction Beta(1,361)BMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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difference in the risk of infection with age and an
increased risk of infection in younger children both
approximated 0.32.
The estimated sensitivity of AFP surveillance for each
jurisdiction based on historical surveillance data is sum-
marised in Table 3, along with sensitivity ratios compar-
ing these estimates with those based on WHO
recommended surveillance practices. The jurisdiction-spe-
cific sensitivity estimates in Table 3 are dependent on the
size of the population under surveillance, and as such can-
not be compared between jurisdictions; however, the sen-
sitivity ratios can be compared. The jurisdictions that had
the highest rate of stool sampling (Queensland and the
Australian Capital Territory) had the highest sensitivity
ratios.
Maximum probability of disease freedom
For surveillance scenarios where the probability of disease
introduction is lower than the surveillance system sensi-
tivity in each surveillance period, the accumulation of
continuous negative surveillance findings enables the sur-
veillance system to establish a higher certainty of disease
freedom than is possible based on the findings of any sin-
gle surveillance period. In these scenarios, the maximum
probability of disease freedom occurs when the value of
additional surveillance information is not associated with
an increased probability of disease freedom due to the risk
of disease importation and temporal discounting of previ-
ous surveillance information.
For surveillance scenarios where the probability of disease
introduction is lower than the surveillance system sensi-
tivity, and these parameters can be considered constant
over time, we found that the deterministic expected equi-
librium posterior probability of disease freedom
(PFreeEquil), which represents a maximum value in the
scenarios examined here, can be estimated based on the
mean probability of disease introduction (pIntro) and
mean surveillance system sensitivity (SSe) using Equation
2. The expected maximum prior probability of freedom in
these scenarios can also be estimated as pIntro/SSe. See
additional file 1: PFreeEquil_proof for the derivation of
this formula.
Equation 2 can be used to understand the scenario tree
model results, and explore the impact of alternative prob-
abilities of disease introduction or surveillance sensitivity
on the maximum (equilibrium) probability of disease
freedom. Estimates of the expected maximum probability
of disease freedom are derived only from parameter mean
values, and differ slightly from the full simulation model
results which are derived from probability distributions.
Based on mean estimates of the probability of introduc-
tion of 0.0028 (Beta(1,361)) and a mean surveillance sys-
tem sensitivity of 0.084, the expected maximum
probability of freedom is 96.9%. The expected maximum
probability of freedom is achieved after approximately 10
years of surveillance given an initial prior probability of
freedom of 0.5, with a probability of 96.0% achieved in
just over 4 years. This expected maximum probability of
freedom estimate is comparable to the simulation mean
probability of freedom of 96.8% following 20 years of
continuous negative surveillance findings. If the probabil-
ity of introduction was assumed to be 0.0006
(Beta(2,3600)), the expected maximum probability of
freedom of 99.4% (which equals the simulation mean
probability of freedom following 20 years of surveillance)
is achieved after approximately 9 years of surveillance,
with a probability of 99.0% achieved in approximately 5
years.
If it is assumed that younger children are at increased risk
of infection, and using a probability of introduction of
0.0028, the expected maximum posterior probability of
freedom of 98.3% is only marginally higher than the
model assuming no age effect, although this maximum
probability is achieved in just over 5 years, with 98.0%
achieved in approximately 3 years. If the probability of
introduction was assumed to be 0.0006, the expected
maximum probability of freedom is 99.7%, and is
achieved after approximately 5 years of surveillance, with
99.0% reached within approximately 3 years.
Discussion
As the world approaches polio eradication, the use of
case-free periods as an indicator of the cessation of disease
transmission becomes increasingly imprecise due to the
high proportion of subclinical infections [46]. We found
that the sensitivity of any single month of AFP surveil-
lance in Australia based on historical data was low,
although continuous negative surveillance over several
years can produce a high level of accumulated surveillance
sensitivity. Our findings emphasise, similar to previous
modelling studies [31,46], that even after five years with-
out a detected case, freedom from poliovirus infection
cannot be assumed.
Sustained sensitive surveillance is required to demon-
strate freedom from poliovirus infection in Australia and
support the prevention of polio re-emergence. Based on
historical surveillance practices, our findings suggest that
establishing over 95% certainty of freedom from poliovi-
rus infection at a design prevalence of 10-5 requires contin-
uous negative surveillance results for approximately four
PFreeEquil plntro SSe plntro for plntro SSe =− − < (( / ) ) / ( ) ( ) 11  
(2)BMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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years assuming no differential risk of infection by age, or
two years if it is assumed that there is an increased risk of
infection in younger children.
Attainment of the target AFP notification rate of 1 case per
100,000 children aged less than 15 years is a critical com-
ponent of the WHO assessment of surveillance adequacy.
There is considerable variation in the rates of AFP reported
internationally [47], and studies suggest that the true rate
of AFP in Australia is not lower than the WHO target rate
[41,42]. Using pooled data we found that the average AFP
notification rate for most jurisdictions was not signifi-
cantly different from the WHO target rate; however, stool
sampling rates were generally significantly lower than the
WHO recommended rate.
The ability of all States and Territories to meet the WHO
surveillance targets, particularly with respect to stool sam-
pling rates, would substantially improve the sensitivity of
surveillance for poliovirus infection in Australia over
short time periods. If the WHO surveillance targets were
achieved in each jurisdiction, only approximately 2 years
of negative surveillance findings would be required to
establish 99% certainty of freedom from poliovirus infec-
tion at a prevalence of 10-5 assuming no differential risk of
infection by age, or 1 year of surveillance if it is assumed
that there is an increased risk of infection among younger
children.
The low rate of stool sampling in Australia compared with
the WHO surveillance target may compromise the timeli-
ness and effectiveness of the public health response in the
event of poliovirus importation or re-emergence [48].
Despite the introduction of a series of strategies to facili-
tate the early notification and stool testing of paediatric
AFP cases, including a large-scale campaign in 1998 [17],
there has been little sustained improvement in notifica-
tion rates. The stool sampling rate among eligible AFP
cases reported in 2007 was the highest on record at 52%
[22], although this remains well below the WHO target
rate. It is clear that there are widespread and longstanding
difficulties in adherence to the WHO recommended stool
sampling procedures in Australia.
The long absence of polio in Australia, the failure of clini-
cians to associate AFP surveillance with non-polio AFP,
and the presence of a confirmed alternative diagnosis
have been identified as contributing to the under-report-
ing in AFP surveillance [17]. Anecdotal evidence suggests
that clinicians are able to rationalise the low rate of stool
sampling on clinical grounds. The unwillingness to obtain
stool samples may be a product of the specialist manage-
ment of cases in Australia, and the availability of sophisti-
cated diagnostic technologies allowing rapid definitive
diagnosis of cases with non-polio AFP. The WHO surveil-
lance criteria have been considered less appropriate for
the evaluation of AFP surveillance in developed commu-
nities with access to sophisticated diagnostic techniques
[17].
More comprehensive stool sampling among AFP cases
would increase the sensitivity of surveillance for poliovi-
rus infection based on the WHO AFP-based surveillance
model. However, the extent to which stool sampling rates
reflect real deficiencies in the timeliness and sensitivity of
AFP surveillance in the context of a population which gen-
erally has good access to a highly skilled specialist medical
workforce remains to be established. Further work is
needed to understand the clinical decision-making proc-
esses leading to the failure to notify or obtain stool sam-
ples from children presenting with AFP, and critically
evaluate the basis of stool sampling for poliovirus surveil-
lance in Australia.
Ensuring sustainable surveillance for polioviruses is a key
challenge facing the Global Polio Eradication Initiative, as
only 20 per cent of countries in polio-free regions are
achieving WHO certification standard surveillance [49].
The sensitivity of AFP surveillance for poliovirus infection
is limited by the high proportion of subclinical infections
and low stool sampling rates. Alternative surveillance
processes may be required to improve the sensitivity of
surveillance in polio-free regions. Environmental surveil-
lance for polioviruses can provide high sensitivity for
poliovirus detection, and may be a useful supplementary
surveillance strategy as global polio eradication
approaches [50,51].
Well developed methods for the analysis of poliovirus sur-
veillance information from multiple sources are also
required to ensure that surveillance is adequate to detect
infection at the desired population prevalence, and that
resources for surveillance are used efficiently. Scenario
tree models provide a transparent and flexible method for
analysis that can integrate accumulated surveillance infor-
mation from multiple surveillance system components
[19]. As demonstrated by the present study, scenario tree
modelling allows the systematic quantitative evaluation
of the adequacy of surveillance systems, accounting for
multiple factors that influence the probability of disease
and the probability of detecting disease.
Uncertainty associated with the probability of introduc-
tion and establishment of poliovirus in Australia is a lim-
itation of this analysis. The probability of poliovirus
introduction and establishment is likely to fluctuate, and
depend on trends in global surveillance and control;
immunity among residents and travellers; and global
mobility. In recognition of the significant risk of poliovi-
rus importation, a World Health Assembly resolution onBMC Infectious Diseases 2009, 9:162 http://www.biomedcentral.com/1471-2334/9/162
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the immunisation of travellers from endemic areas has
been proposed [4] to reduce the international spread of
polioviruses.
Global eradication of polio remains achievable [7], and
certification of the world as free of indigenous wild polio-
virus is expected to occur three years after the last case of
polio has been identified [52]. Although the risk of polio
resurgence following certification is considered remote
[52], the sensitivity of global surveillance is of critical
importance in evaluating the likelihood of interrupting
poliovirus transmission and disease freedom. Scenario
tree modelling provides a valuable tool for systematically
assessing the effectiveness of surveillance for poliovirus
infection and identifying gaps in surveillance. The limita-
tions of global surveillance, where they exist, need to be
recognised and remedied to ensure progress towards dis-
ease eradication.
Conclusion
Effective surveillance systems are critical for the global
eradication of polio. Ensuring a high probability of free-
dom from poliovirus infection in Australia at a low level
of disease prevalence requires sensitive long-term surveil-
lance. The low rate of stool sampling among notified cases
is an important modifiable factor contributing to the low
sensitivity of AFP surveillance in Australia compared with
WHO surveillance targets. Our findings emphasise the
importance of maintaining sensitive surveillance beyond
the period required for WHO certification, both to sup-
port global progress towards polio eradication, and to
enable effective public health response in the event of the
importation or re-emergence of polio.
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